Search

Your search keyword '"Toth, A. G."' showing total 18 results
Start Over Author "Toth, A. G." Publication Year Range This year
18 results on '"Toth, A. G."'

3. Correction: Intentional coronary revascularization versus conservative therapy in patients after peripheral artery revascularization due to critical limb ischemia: the INCORPORATE trial

Author

Toth, Gabor G, Brodmann, Marianne, Schnur, Sadeek S Kanoun, Bartus, Stanislaw, Vrsalovic, Mislav, Krestianinov, Oleg, Kala, Petr, Bil, Jacek, Gil, Robert, Kanovsky, Jan, Di Serafino, Luigi, Paolucci, Luca, Barbato, Emanuele, Mangiacapra, Fabio, and Ruzsa, Zoltan

Published
2024
Full Text
View/download PDF

4. In-hospital Outcomes of Rotational Atherectomy in ST-Elevation Myocardial Infarction: Results From the Multicentre ROTA-STEMI Network

Author

Hemetsberger, Rayyan, Mankerious, Nader, Muntané-Carol, Guillem, Temporal, Justin, Sulimov, Dmitriy, Gaede, Luise, Woitek, Felix, Grau, Edgar Fadeuilhe, Scalamogna, Maria, Olschewski, Maximilian, Mitsis, Andreas, Ruzsa, Zoltán, Toth, Gabor G., Heyer, Hajo, Toelg, Ralph, Gómez-Hospital, Joan A., Mügge, Andreas, Hengstenberg, Christian, Mangner, Norman, Gori, Tommaso, Cassese, Salvatore, Suárez, Xavier Carrillo, Abdel-Wahab, Mohamed, Johnson, Thomas, Richardt, Gert, and Allali, Abdelhakim

Published
2024
Full Text
View/download PDF

5. Differential Impact of Fractional Flow Reserve Measured After Coronary Stent Implantation by Left Ventricular Dysfunction

Author

Choi, Ki Hong, Kwon, Woochan, Shin, Doosup, Lee, Seung-Hun, Hwang, Doyeon, Zhang, Jinlong, Nam, Chang-Wook, Shin, Eun-Seok, Doh, Joon-Hyung, Chen, Shao-Liang, Kakuta, Tsunekazu, Toth, Gabor G., Piroth, Zsolt, Hakeem, Abdul, Uretsky, Barry F., Hokama, Yohei, Tanaka, Nobuhiro, Lim, Hong-Seok, Ito, Tsuyoshi, Matsuo, Akiko, Azzalini, Lorenzo, Leesar, Massoud A., Daemen, Joost, Collison, Damien, Collet, Carlos, De Bruyne, Bernard, Koo, Bon-Kwon, Park, Taek Kyu, Yang, Jeong Hoon, Song, Young Bin, Hahn, Joo-Yong, Choi, Seung-Hyuk, Gwon, Hyeon-Cheol, and Lee, Joo Myung

Published
2024
Full Text
View/download PDF

6. Two-year results from Onyx ONE clear in patients with high bleeding risk on one-month DAPT with and without intracoronary imaging

Author

Toth, Gabor G., Kandzari, David E., Kirtane, Ajay J., Windecker, Stephan, Latib, Azeem, Kedhi, Elvin, Mehran, Roxana, Price, Matthew J., Choi, James W., Caputo, Ronald, Troquay, Roel, Diderholm, Erik, Singh, Sunil, Brar, Somjot S., Loussararian, Arthur, Chetcuti, Stanley, Tulli, Mark, Stone, Gregg W., Lung, Te-Hsin, and Mylotte, Darren

Published
2024
Full Text
View/download PDF

8. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years

Author

Barkai, Laszlo Jozsef, primary, Gonczi, Lorant, additional, Balogh, Fruzsina, additional, Angyal, Dorottya, additional, Farkas, Klaudia, additional, Farkas, Bernadett, additional, Molnar, Tamas, additional, Szamosi, Tamas, additional, Schafer, Eszter, additional, Golovics, Petra A., additional, Juhasz, Mark, additional, Patai, Arpad, additional, Vincze, Aron, additional, Sarlos, Patricia, additional, Farkas, Alexandra, additional, Dubravcsik, Zsolt, additional, Toth, Tamas G., additional, Szekely, Hajnal, additional, Miheller, Pal, additional, Lakatos, Peter L., additional, and Ilias, Akos, additional

Published
2024
Full Text
View/download PDF

9. Impact of the Timing of Mechanical Circulatory Support on the Outcomes in Myocardial Infarction-Related Cardiogenic Shock: Subanalysis of the PREPARE CS Registry

Author

Prunea, Dan M., primary, Bachl, Eva, additional, Herold, Lukas, additional, Kanoun Schnur, Sadeek S., additional, Pätzold, Sascha, additional, Altmanninger-Sock, Siegfried, additional, Sommer, Gudrun A., additional, Glantschnig, Theresa, additional, Kolesnik, Ewald, additional, Wallner, Markus, additional, Ablasser, Klemens, additional, Bugger, Heiko, additional, Buschmann, Eva, additional, Praschk, Andreas, additional, Fruhwald, Friedrich M., additional, Schmidt, Albrecht, additional, von Lewinski, Dirk, additional, and Toth, Gabor G., additional

Published
2024
Full Text
View/download PDF

10. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years.

Author

Barkai, Laszlo J., Gonczi, Lorant, Balogh, Fruzsina, Angyal, Dorottya, Farkas, Klaudia, Farkas, Bernadett, Molnar, Tamas, Szamosi, Tamas, Schafer, Eszter, Golovics, Petra A., Juhasz, Mark, Patai, Arpad, Vincze, Aron, Sarlos, Patricia, Farkas, Alexandra, Dubravcsik, Zsolt, Toth, Tamas G., Szekely, Hajnal, Miheller, Pal, and Lakatos, Peter L.

Subjects
CROHN'S disease, INFLAMMATORY bowel diseases, DISEASE remission
Abstract

Long-term data on ustekinumab in real-life Crohn's disease patients are still missing, though randomized controlled trials demonstrated it as a favorable therapeutic option. We aimed to evaluate ustekinumab's clinical efficacy, drug sustainability, and safety in a prospective, nationwide, multicenter Crohn's disease patient cohort with a three-year follow-up. Crohn's disease patients on ustekinumab treatment were consecutively enrolled from 9 Hungarian Inflammatory Bowel Disease centers between January 2019 and May 2020. Patient and disease characteristics, treatment history, clinical disease activity (Harvey Bradshaw Index (HBI)), biomarkers, and endoscopic activity (Simple Endoscopic Score for Crohn's Disease (SES-CD)) were collected for three-years' time. A total of 148 patients were included with an overall 48.9% of complex behavior of the Crohn's disease and 97.2% of previous anti-TNF exposure. The pre-induction remission rates were 12.2% (HBI), and 5.1% (SES-CD). Clinical remission rates (HBI) were 52.2%, 55.6%, and 50.9%, whereas criteria of an endoscopic remission were fulfilled in 14.3%, 27.5%, and 35.3% of the subjects at the end of the first, second, and third year, respectively. Dose intensification was high with 84.0% of the patients on an 8-weekly and 29.9% on a 4-weekly regimen at the end of year 3. Drug sustainability was 76.9% during the follow-up period with no serious adverse events observed. Ustekinumab in the long-term is an effective, sustainable, and safe therapeutic option for Crohn's disease patients with severe disease phenotype and high previous anti-TNF biological failure, requiring frequent dose intensifications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. P661 Ustekinumab in Crohn’s disease: A three-year multicentre prospective study from Hungary - Assessing efficacy, drug sustainability, and safety

Author

Barkai, L J, primary, Gonczi, L, additional, Farkas, K, additional, Farkas, B, additional, Molnar, T, additional, Szamosi, T, additional, Schafer, E, additional, Golovics, P, additional, Juhasz, M, additional, Patai, A, additional, Vincze, A, additional, Sarlos, P, additional, Farkas, A, additional, Dubravcsik, Z, additional, Toth, T G, additional, Miheller, P, additional, Lakatos, P L, additional, and Ilias, A, additional

Published
2024
Full Text
View/download PDF

13. Temporal changes in coronary plaque as assessed by an artificial intelligence–based optical coherence tomography: from the first-in-human trial on DREAMS 3G scaffold.

Author

Garcia-Garcia, Hector M, Waksman, Ron, Melaku, Gebremedhin D, Garg, Mohil, Beyene, Solomon, Wlodarczak, Adrian, Kerai, Ajay, Levine, Molly B, Schaaf, René J van der, Torzewski, Jan, Ferdinande, Bert, Escaned, Javier, Iglesias, Juan F, Bennett, Johan, Toth, Gabor G, Joner, Michael, Toelg, Ralph, Wiemer, Marcus, Olivecrona, Göran, and Vermeersch, Paul

Subjects
WOUND healing, RESEARCH funding, ARTIFICIAL intelligence, OPTICAL coherence tomography, HEART assist devices, LIPIDS, DESCRIPTIVE statistics, PRE-tests & post-tests, CALCIUM, CORONARY arteries, COMPUTER-aided diagnosis, MESENCHYME tumors, PERCUTANEOUS coronary intervention, CORONARY artery disease, COMPARATIVE studies, DISEASE progression, PATIENT aftercare, DRUG-eluting stents
Abstract

Aims The aim of the study is to assess the impact of the baseline plaque composition on the DREAMS 3G luminal late loss and to compare the serial plaque changes between baseline and 6 and 12 months (M) follow-up. Methods and results A total of 116 patients were enrolled in the BIOMAG-I trial. Patients were imaged with optical coherence tomography (OCT) pre- and post-DREAMS 3G implantation and at 6 and 12 M. OCTPlus software uses artificial intelligence to assess composition (i.e. lipid, calcium, and fibrous tissue) of the plaque. The differences between the OCT-derived minimum lumen area (MLA) post-percutaneous coronary intervention and 12 M were grouped into three terciles. Patients with larger MLA differences at 12 M (P = 0.0003) had significantly larger content of fibrous tissue at baseline. There was a reduction of 24.8% and 20.9% in lipid area, both P < 0.001, between the pre-DREAMS 3G OCT and the 6 and 12 M follow-up. Conversely, the fibrous tissue increased by 48.4% and 36.0% at 6 and 12 M follow-up, both P < 0.001. Conclusion The larger the fibrous tissue in the lesion at baseline, the larger the luminal loss seen at 6 and 12 M. Following the implantation of DREAMS 3G, favourable healing of the vessel coronary wall occurs as shown by a decrease in the lipid area and an increase in fibrous tissue. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Knowledge.

Author

Toth, Imre G. and Korn, Bob

Subjects
*GODS, CHRISTIAN attitudes
Published
2024

18. Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.

Author

Thiele, Holger, Desch, Steffen, Zeymer, Uwe, Mallidi, Jaya, Lotfi, Amir, From, Aaron M., Elkaryoni, Ahmed, Hyder, Omar, Saad, Marwan, Baldetti, Luca, Pieri, Marina, Scandrogiio, Anna Mara, von Lewinski, Dirk, Herold, Lukas, and Toth, Gabor G.

Subjects
*CARDIOGENIC shock, *EXTRACORPOREAL membrane oxygenation, *ST elevation myocardial infarction
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results